$STIM

Neuronetics (STIM) reported Q2 2026 revenue of $41.6M, up 9.1% YoY. Greenbrook revenue grew 16.8% YoY, while NeuroStar revenue fell 2.7% YoY. Net loss narrowed to $3.4M. Full-year revenue guidance was set at $160M-$164M, with gross margin guidance raised to 48%-50%. The company expanded NeuroStar acquisition options and integrated AI into operations. Management highlighted growth opportunities in psychedelic-based therapies and strategic collaborations.

Neuronetics, Inc. (STIM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On August 11, 2026, in connection with Mr. Naor’s appointment (as described below), Francis X. Brown III’s appointment

Chernett Jorey purchased 14,000 shares of Neuronetics, Inc. (STIM) at $3.16 on 2026-08-14.

Neuronetics reported Q2 2026 progress on its NeuroStar commercial shift to hybrid capital purchase and lease options, with 17% YoY growth at Greenbrook clinics and a 10% utilization increase in active NeuroStar accounts. Management expects choppier H2 2026 revenue, raised full-year gross margin guidance to 48%-50%, and cut operating expense guidance by $5M.

Neuronetics (NASDAQ:STIM) reported Q2 Worldwide NeuroStar revenue of $14.7M, down 2.7% YoY, with capital revenue up and treatment-session revenue down. The company expanded NeuroStar purchase and leasing options, expects no further material inventory reduction in H2, and plans to report NeuroStar as a single revenue line. Gross margin rose to 61.1% and 2026 guidance was narrowed to $160M-$164M.

Neuronetics (STIM) reported Q2 2026 revenue of $41.6 million, up 9.1% year over year, with Greenbrook revenue rising 16.8% to $26.9 million. Gross margin increased to 51.1%. Adjusted EBITDA turned positive at $0.3 million. Net loss narrowed to $3.4 million. Full-year 2026 revenue guidance is $160-$164 million and gross margin 48%-50%.

Neuronetics shares rose about 24% in pre-open after the company reported Q2 2026 results that beat Wall Street on revenue and EPS. Revenue was $41.6M (+9.1% YoY). Net loss narrowed to $3.4M, or -$0.05/share, versus -$10.1M and -$0.15/share a year earlier. Greenbrook revenue grew to $26.9M (+16.8%).

Neuronetics, Inc. (STIM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Neuronetics Reports Second Quarter 2026 Financial and Operating Results MALVERN, PA., August 11, 2026 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health that combines its NeuroStar ® TMS technology with direc

Neuronetics (NASDAQ: STIM) said it held the grand opening of Greenbrook Mental Wellness Centers’ National Center of Excellence in Rockville, Maryland. The nearly 7,000-square-foot facility, overseen by Neuronetics CEO Geoffrey Grammer, is described as the largest Greenbrook center to date and intended to expand access to interventional psychiatry and support clinical innovation.

Biotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).